Literature DB >> 26138512

High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype.

Youssef Bennis1, Sandra Bodeau1, Régis Bouquié2, Guillaume Deslandes2, Céline Verstuyft3, Bérangère Gruson4, Michel Andréjak5, Anne-Sophie Lemaire-Hurtel5, Taieb Chouaki6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26138512      PMCID： PMC4594719          DOI： 10.1111/bcp.12713

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  10 in total

1.  A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine.

Authors:  Mirte M Malingré; Peggy C R Godschalk; Saskia K Klein
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

2.  Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.

Authors:  Maud Berge; Romain Guillemain; David A Trégouet; Catherine Amrein; Veronique Boussaud; Patrick Chevalier; Agnes Lillo-Lelouet; Christine Le Beller; Pierre Laurent-Puig; Philippe H Beaune; Eliane M Billaud; Marie-Anne Loriot
Journal:  Eur J Clin Pharmacol       Date:  2010-10-31       Impact factor: 2.953

3.  CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.

Authors:  Johanna Weiss; Magdalena Maria Ten Hoevel; Jürgen Burhenne; Ingeborg Walter-Sack; Michael Marcus Hoffmann; Jens Rengelshausen; Walter E Haefeli; Gerd Mikus
Journal:  J Clin Pharmacol       Date:  2008-11-25       Impact factor: 3.126

4.  Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.

Authors:  Arwa Hassan; Jürgen Burhenne; Klaus-Dieter Riedel; Johanna Weiss; Gerd Mikus; Walter E Haefeli; David Czock
Journal:  Ther Drug Monit       Date:  2011-02       Impact factor: 3.681

5.  Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort.

Authors:  J A Trubiano; A Crowe; L J Worth; K A Thursky; M A Slavin
Journal:  J Antimicrob Chemother       Date:  2015-01-03       Impact factor: 5.790

6.  The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.

Authors:  Wan Beom Park; Nak-Hyun Kim; Kye-Hyung Kim; Seung Hwan Lee; Won-Seok Nam; Seo Hyun Yoon; Kyoung-Ho Song; Pyoeng Gyun Choe; Nam Joong Kim; In-Jin Jang; Myoung-Don Oh; Kyung-Sang Yu
Journal:  Clin Infect Dis       Date:  2012-07-03       Impact factor: 9.079

7.  Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.

Authors:  Michael J Dolton; Gerd Mikus; Johanna Weiss; John E Ray; Andrew J McLachlan
Journal:  J Antimicrob Chemother       Date:  2014-02-18       Impact factor: 5.790

8.  Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.

Authors:  Ina Scholz; Heike Oberwittler; Klaus-Dieter Riedel; Jürgen Burhenne; Johanna Weiss; Walter E Haefeli; Gerd Mikus
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

9.  Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.

Authors:  J Kevin Hicks; Kristine R Crews; Patricia Flynn; Cyrine E Haidar; Calvin C Daniels; Wenjian Yang; John C Panetta; Deqing Pei; Jeffrey R Scott; Alejandro R Molinelli; Ulrich Broeckel; Deepa Bhojwani; William E Evans; Mary V Relling
Journal:  Pharmacogenomics       Date:  2014-06       Impact factor: 2.533

10.  Steady-state pharmacokinetics and metabolism of voriconazole in patients.

Authors:  Marcus J P Geist; Gerlinde Egerer; Jürgen Burhenne; Klaus-Dieter Riedel; Johanna Weiss; Gerd Mikus
Journal:  J Antimicrob Chemother       Date:  2013-06-13       Impact factor: 5.790
  10 in total
  2 in total

1.  PharmGKB summary: voriconazole pathway, pharmacokinetics.

Authors:  Julia M Barbarino; Aniwaa Owusu Obeng; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2017-05       Impact factor: 2.089

2.  High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness.

Authors:  L Bernal-Martínez; L Alcazar Fuoli; B Miguel-Revilla; A Carvalho; M S Cuétara Garcia; J Garcia-Rodriguez; C Cunha; E Gómez-García de la Pedrosa; A Gomez-Lopez
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.